Abstract
The ability of antisense oligonucleotides to interdict, sequence-specifically, the expression of pathogenic genes affords an exciting new strategy for therapeutic intervention (1–3). Oligonucleotides with physiological phosphodiester internucleotide bonds are rapidly degraded, predominantly by exonucleases. Numerous oligonucleotide analogs have therefore been synthesized to confer resistance toward nuclease activity (3). The phosphorothioate analog is the most extensively studied, and phosphorothioate oligodeoxynucleotides have been shown to be potent inhibitors of the expression of their target genes in vitro and in vivo (1,3). However, phosphorothioate oligodeoxynucleotides also bind avidly and nonspecifically to proteins, thus provoking a variety of non-antisense effects (4). Oligonucleotide analogs that do not bind to proteins are therefore expected to display less nonantisense side effects. However, protein binding also affects the in vivo disposition of oligonucleotides. Nonphosphorothioate oligonucelotide analogs generally do not bind to serum proteins, and are therefore rapidly cleared from the circulation, protein-bound phosphorothioate oligodeoxynucelotides circulate much longer (5,6).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Akhtar S. and Agrawal S. (1997) In vivo studies with antisense oligonucleotides. Trends Pharm. Sci. 18, 12–18.
Branch A. D. (1996) Hitchhiker’s guide to antisense and nonantisense biochemical pathways. Hepatology 24, 1517–1529.
Szymkowski D. E. (1996) Developing antisense oligonucleotides from the laboratory to the clinic. Drug Discov. Today 1, 415–428.
Stein C. A. (1995). Does antisense exist? Nature Med. 1, 1119–1121.
Sands H., Gorey-Feret L. J., Cocuzza A, J., Hobbs F. W., Chidester D., and Trainor G. L. (1994) Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol. Pharmacol. 45, 932–943.
Nolting A., DeLong R. K., Fisher M. H., Wickstrom E., Pollack G. M., Juliano R. L., and Brouwer K. L. (1997) Hepatic distribution and clearance of antisense oligonucleotides in the isloated perfused rat liver. Pharm. Res. 14, 516–521.
Brown M. S. and Goldstein J. L. (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34–47.
Harkes L. and van Berkel T. J. C. (1983) Cellular localization of the receptor-dependent and receptor-independent uptake of human LDL in the liver of normal and 17 alpha-ethinyl estradiol-treated rats. FEBS Lett. 154, 75–80.
Firestone R. A. (1994) Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjugate Chem. 5, 105–113.
Majello B., Kenyon L. C., and Dalla-Favera R. (1986) Human c-myb protooncogene: nucleotide sequence of cDNA and organization of the genomic locus. Proc. Nat. Acad. Sci. USA 83, 9636–9640.
Rump E. T., de Vrueh R. L. A., Sliedregt L. A. J. M., Biessen E. A. L., van Berkel T. J. C., and Bijsterbosch M. K. (1998) Preparation of conjugates of oligonucleotides and lipid structures, and their interaction with low-density lipoprotein. Bioconjugate Chem. 9, 341–349.
Graham M. J., Freier S. M., Crooke R. M., Ecker D. J., Maslova R. N., and Lesnik E. A. (1993) Tritium labeling of antisense oligonucleotides by exchange with tritiated water. Nucleic Acids Res. 21, 3737–3743.
Bijsterbosch M. K., Rump E. T., De Vrueh R. L. A., Dorland R., Van Veghel R., Tivel K. L., et al. (2000) Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol modification. Nucleic Acids Res. 28, 2717–2725.
Manoharan M., Tivel K. L., and Cook P. D. (1995) Lipidic nucleic acids. Tetrahedron Lett. 36, 3651–3654.
Firestone R. A., Pisano J. M., Falck J. R., McPaul M. M., and Krieger M. (1984) Selective delivery of cytotoxic compounds to cells by the LDL pathway. J. Med. Chem. 27, 1037–1043.
Rensen P. C. N., Herijgers N., Netscher M. H., Meskers S. C. J., van Eck M., and van Berkel T. J. C. (1997) Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. J. Lipid Res. 38, 1070–1084.
Rensen P. C. N., Schiffelers R. M., Versluis A. J., Bijsterbosch M. K., van Kuijk-Meuwissen M. E. M. J., and van Berkel T. J. C. (1997) Human recombinant apolipoprotein E-enriched liposomes can mimic low density lipoproteins as carriers for the site-specific delivery of anti-tumour agents. Mol. Pharmacol. 52, 445–454.
Redgrave T. G., Roberts D. L. K., and West C. E. (1975) Separation of plasma lipoproteins by density gradient ultracentrifugation. Anal. Biochem. 65, 42–49.
McFarlane A. S. (1958) Efficient trace-labelling of proteins with iodine. Nature 182, 53–54.
Lowry O. H., Rosebrough N. J., Farr A. L., and Randall R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265–275.
Chen S. H., Yang C. Y., Chen P. F., Setzer D., Tanimuara M., Li W. H., Gotto A. M., Jr., and Chan L. (1986) The complete cDNA and amino acid sequence of human apolipoprotein B-100. J. Biol. Chem. 261, 12,918–12,921.
Cossum P. A., Sasmor H., Dellinger D., Truong L., Cummins L., Owens S. R., et al. (1993) Disposition of the C-14-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267, 1181–1190.
Srinivasan S. K., Tewary H. K., and Iversen P. L. (1995) Characterization of binding sites, extent of binding, and drug interactions of oligonucleotides with albumin. Antisense Res. Dev. 5, 131–139.
Bijsterbosch M. K., Duursma A. M., Bouma J. M. W., and Gruber M. (1981) The plasma volume of the Wistar rat in relation to the body weight. Experientia 37, 381–382.
Rump E. T., de Vrueh R. L. A., Manoharan M., Waarlo I. H. E., van Veghel R., Biessen E. A. L., van Berkel T. J. C., and Bijsterbosch M. K. (2000) modification of the plasma clearance and liver uptake of steroid ester-conjugated oligodeoxynucleotides by association with (lactosylated) low-density lipoprotein. Biochem. Pharmacol. 59, 1407–1416.
Biessen E. A. L., Vietsch H., Kuiper J., Bijsterbosch M. K., and van Berkel T. J. C. (1998) Liver uptake of phosphodiester oligodeoxynucleotides is mediated by scavenger receptors. Mol. Pharmacol. 53, 262–269.
Summerton J. (1999) Morpholino antisense oligomers: the case for an RNAse H-independent structural type. Biochim. Biophys. Acta 1489, 141–158.
Larsen H. J., Bentin T., and Nielsen P. E. (1999) Antisense properties of peptide nucleic acid. Biochim. Biophys. Acta 1489, 159–166.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Humana Press Inc.
About this protocol
Cite this protocol
Rump, E.T., Biessen, E.A.L., van Berkel, T.J.C., Bijsterbosch, M.K. (2001). Interactions of Lipid-Oligonucleotide Conjugates with Low-Density Lipoprotein. In: Findeis, M.A. (eds) Nonviral Vectors for Gene Therapy. Methods in Molecular Medicine™, vol 65. Humana Press. https://doi.org/10.1385/1-59259-139-6:89
Download citation
DOI: https://doi.org/10.1385/1-59259-139-6:89
Publisher Name: Humana Press
Print ISBN: 978-0-89603-712-0
Online ISBN: 978-1-59259-139-8
eBook Packages: Springer Protocols